BACKGROUND:
Myocardial metabolic impairment is a major feature in chronic heart failure. As the major coenzyme in fuel oxidation and oxidative phosphorylation and a substrate for enzymes signaling energy stress and oxidative stress response, nicotinamide adenine dinucleotide (NAD + ) is emerging as a metabolic target in a number of diseases including heart failure. Little is known on the mechanisms regulating homeostasis of NAD + in the failing heart.
METHODS:
To explore possible alterations of NAD + homeostasis in the failing heart, we quantified the expression of NAD + biosynthetic enzymes in the human failing heart and in the heart of a mouse model of dilated cardiomyopathy (DCM) triggered by Serum Response Factor transcription factor depletion in the heart (SRF HKO ) or of cardiac hypertrophy triggered by transverse aorta constriction. We studied the impact of NAD + precursor supplementation on cardiac function in both mouse models.
RESULTS:
We observed a 30% loss in levels of NAD + in the murine failing heart of both DCM and transverse aorta constriction mice that was accompanied by a decrease in expression of the nicotinamide phosphoribosyltransferase enzyme that recycles the nicotinamide precursor, whereas the nicotinamide riboside kinase 2 (NMRK2) that phosphorylates the nicotinamide riboside precursor is increased, to a higher level in the DCM (40-fold) than in transverse aorta constriction (4-fold) . This shift was also observed in human failing heart biopsies in comparison with nonfailing controls. We show that the Nmrk2 gene is an AMP-activated protein kinase and peroxisome proliferator-activated receptor α responsive gene that is activated by energy stress and NAD + depletion in isolated rat cardiomyocytes. Nicotinamide riboside efficiently rescues NAD + synthesis in response to FK866-mediated inhibition of nicotinamide phosphoribosyltransferase and stimulates glycolysis in cardiomyocytes. Accordingly, we show that nicotinamide riboside supplementation in food attenuates the development of heart failure in mice, more robustly in DCM, and partially after transverse aorta constriction, by stabilizing myocardial NAD + levels in the failing heart. Nicotinamide riboside treatment also robustly increases the myocardial levels of 3 metabolites, nicotinic acid adenine dinucleotide, methylnicotinamide, and N1-methyl-4-pyridone-5-carboxamide, that can be used as validation biomarkers for the treatment.
CONCLUSIONS:
The data show that nicotinamide riboside, the most energyefficient among NAD precursors, could be useful for treatment of heart failure, notably in the context of DCM, a disease with few therapeutic options.
D
espite progress in therapeutic advances, mortality remains high in congestive heart failure (HF), creating a need for new evidence-based and cost-effective treatments. Failure of cardiomyocyte bioenergetics is a key issue in HF that is not well addressed in current therapeutics. 1, 2 We focused our attention on pathways that regulate nicotinamide adenine dinucleotide (NAD + ) homeostasis in the failing heart, which has emerged as a new avenue for the development of metabolic therapy of HF.
3,4 NAD + is the major hydride transfer coenzyme in fuel oxidation and mitochondrial ATP generation and is the precursor for NADPH, which is required for anabolic pathways and reactive oxygen species detoxification. 5, 6 In addition, NAD + is an essential substrate of enzymes including sirtuins and poly(ADP-ribose) polymerases, which are important in responding to altered nutritional status and genotoxic stress. 6, 7 Sirtuins perform NAD + -dependent deacylation of protein Lys residues modified by acetyl coenzyme A (Ac-CoA) derived acyl groups. 8 Sirtuins regulate nuclear gene expression, and mitochondrial enzyme activities, as well, and can play a protective role in the heart, 9 although chronic overactivation may be deleterious. 10 Poly(ADP-ribose) polymerase 1 is activated by reactive oxygen species-induced DNA lesions, and could deplete myocardial NAD + stores in HF. 11 In situations of physiological equilibrium, biosynthetic pathways relying on dietary sources of tryptophan and NAD + precursor vitamins counterbalance the consumption of NAD + by signaling enzymes. However, dietary precursors may become insufficient to maintain the NAD + metabolome in pathological conditions, thereby necessitating supplementation of NAD + precursor. 5, 12, 13 The homeostasis of NAD + and regulation of NAD + biosynthetic enzymes have not been studied in dilated cardiomyopathy (DCM), a leading cause of heart transplant. 14 We previously generated a powerful model of nonischemic DCM in mice triggered by cardiac-specific inducible inactivation of Serum Response Factor (SRF-HKO model). [15] [16] [17] [18] SRF is a major transcriptional regulator of genes and microRNAs involved in contractility, and in energy flux and calcium handling, as well. 15, 17, 18 The SRF pathway is altered in the human failing heart 19, 20 and in animal models of DCM. 21, 22 The heart of SRF HKO mutant mice display an early downregulation of myofibrillar creatine kinase (CK) activity encoded by the Ckm gene, which is followed by repression of enzymes of fatty acid β-oxidation and loss of ATP, thus recapitulating the transitional steps toward energy failure and cardiac structural remodeling in HF. 18 Here, we show that NAD + homeostasis is altered at an early stage in the heart of SRF HKO mice with a striking induction of the nicotinamide riboside kinase 2 (NMRK2) pathway for NAD + synthesis. Nmrk2 gene is 1 of 2 mammalian paralogs of the yeast NRK1 gene that was discovered as a eukaryotic route to NAD + from nicotinamide riboside (NR). 23 Given the activity of NR in promoting sirtuin activity and restoring metabolic balance in a variety of model organisms, 13, [24] [25] [26] [27] [28] we aimed to test whether NR might treat HF in SRF HKO mice and in the pressure overload hypertrophy model induced by transverse aorta constriction (TAC). Here, we show that NR greatly protects cardiac function by virtue of improved citrate and Ac-CoA metabolism and antioxidant gene expression. Because NR is orally available in people, 29 our data rationalize clinical testing of NR in human HF.
METHODS
The data, analytic methods, and study materials will be made available from the corresponding author on request to other researchers for purposes of reproducing the results or replicating the procedure. Detailed methods are available in the online-only Data Supplement.
Clinical Perspective
What Is New?
• Myocardial nicotinamide adenine dinucleotide (NAD) coenzyme levels are depressed in mouse models of heart failure.
• An expression shift occurs in murine and human failing hearts in which the normally predominant nicotinamide phosphoribosyltransferase enzyme using nicotinamide as a precursor for NAD + synthesis is repressed, whereas the nicotinamide riboside kinase 2 enzyme using the nucleoside nicotinamide riboside (NR) is strongly upregulated.
• The nicotinamide riboside kinase 2pathway is activated by energy stress in an AMP-activated protein kinase α/peroxisome proliferator-activated receptor α-dependent manner in cardiomyocytes.
• NR-supplemented diet administrated to murine models of dilated cardiomyopathy or pressure overload-induced heart failure restores myocardial NAD levels and preserves cardiac function.
• NR increases glycolysis, and citrate and acetyl-coenzyme A metabolism, as well, in cardiomyocytes.
What Are the Clinical Implications?
• NR is the most energetically favorable NAD precursor and was recently shown to be uniquely and orally bioavailable in humans in a phase I clinical trial.
• NR-supplemented diet could help patients who have heart failure to cope with limited myocardial ATP supply by restoring NAD coenzyme levels and associated signaling.
• NR-supplemented diet has been shown in several studies to enhance metabolic flexibility in the context of obesity and diabetes mellitus and to improve muscle function, justifying that NR is put in the front line for metabolic therapy of heart failure syndrome in which these functions are altered. 
Transgenic Mice
All experiments with animals conformed to the Directive 2010/63/EU of the European Parliament and were approved by the ethics committee Charles Darvin #5 (agreement 00369.01). See online-only Data Supplement for details on SRF inactivation protocol.
NR Supplementation

SRF
HKO and control (Sf/Sf) mice were administered A04 rodent maintenance diet (Scientific Animal Food Engineering) supplemented with NR chloride provided by Chromadex. See online-only Data Supplement for details.
Transcriptomic Analysis
Transcriptomic data are available on NCBI Gene Expression Database, Accession number GSE84142.
Statistical Analysis
Animals were randomly assigned into different treatment groups. To assess significance, we performed Student t test for independent samples when the experimental design compared only 2 groups, or 1-way ANOVA for multiple group comparisons, or 2-way factorial ANOVA for independent factors when appropriate. Tukey tests were used for comparison of specific experimental groups when 1-way ANOVA gave a P value of <0.05 or, in the case of 2-way ANOVA for interaction, a P value of <0.05. Values are expressed as mean±SEM.
Supplemental Information
Supplemental information includes supplemental methods, 9 supplemental figures, and 6 supplemental tables.
RESULTS
NMRK2 Pathway Is Activated in the Failing Heart of SRF HKO Mice
Transcriptome analyses in SRF HKO mice at baseline or after phenylephrine α-adrenergic stimulation 16 revealed that the Nmrk2 gene was induced at an early stage in the SRF HKO heart and rose continuously during establishment of HF ( Figure 1A and Table II (Table  II in the online-only Data Supplement). In contrast, the transcripts encoding nicotinamide phosphoribosyltransferase (NAMPT), the enzyme converting nicotinamide (NAM) to NMN, and purine nucleoside phosphorylase (PNP), which converts NR to NAM, 32 were depressed on phenylephrine treatment in SRF HKO hearts (Table II in the online-only Data Supplement). Genes involved in the tryptophan and nicotinic acid pathways for NAD + synthesis were not altered ( Figure 1A and Table II in the online-only Data Supplement).
Modulation of Nmrk2 and Nampt gene expression detected by transcriptomics was corroborated at the mRNA and protein level ( Figure 1B through 1D) . We observed a similar shift in human patients from predominant expression of NAMPT in healthy hearts to increased NMRK2 and depressed NAMPT in failing hearts ( Figure 1D , Table II in the online-only Data Supplement). In mouse heart sections, NMRK2 protein localizes at the proximity of sarcolemma in controls ( Figure 1E ). The signal was strongly enhanced and spread to cytoplasm in SRF HKO cardiomyocytes. At day 15 after SRF inactivation, there was a 30% loss of NAD (representing the sum of NAD + and NADH) ( Figure 1F , see Methods in the online-only Data Supplement for details). The gene expression pattern (Nt5e and Nmrk2 up with Pnp and Nampt down) suggested that cardiac tissue is attempting to mobilize and utilize NR as an NAD + precursor while not increasing NAM usage. We tested this hypothesis by intraperitoneal administration of NR and NAM to SRF HKO mice from day 8 to 15. Consistent with this hypothesis, myocardial NAD levels were preserved by NR but not by NAM ( Figure 1F ). Srf and Nmrk2 expression levels were not changed by these treatments (Figure 1G and 1H). Because NR is orally available, 26, 29 we tested an NR-supplemented diet for 2 weeks. Myocardial NAD levels were reduced in this second series of SRF HKO mice in comparison with controls and rescued by NR administration ( Figure 1I ).
NR Preserves Cardiac Function in the SRF HKO Heart
We hypothesized that NR supplementation of food might be beneficial for cardiac function in the context of DCM. We fed control and mutant SRF HKO mice a standard chow diet or NR-supplemented diet to reach a dose of 400 mg/kg of body weight per day from day 5 to 50, a period in which untreated SRF HKO modest 5% to 7% increase in body weight in control mice and allowed SRF HKO mice to regain weight after an initial loss, whereas SRF HKO mice on a regular diet had lost weight at the end of the protocol (Figure 2A ). Cardiac parameters were analyzed by echocardiography between days 45 and 47 ( Figure 2B through 2O). NR did not change heart rate and LV mass index, but slightly it increased the LV thickness-to-radius ratio (H/R) in control mice ( Figure 2N ). To assess a potential impact of NR treatment on vascular function, we compared vascular reactivity in isolated mesenteric arteries from NR-fed and control mice. We found no difference between the 2 groups neither in responses to K + or agonist-induced contraction nor in the relaxation response to carbachol or a NO donor ( Figure I in the online-only Data Supplement and Table III in the online-only Data Supplement).
SRF HKO mutant mice fed the standard diet displayed a severe decrease in LV ejection fraction and fractional shortening ( Figure 2D and 2E). The NR diet clearly protected against this decline in cardiac function. It is important to note that NR fully protected SRF HKO mice against the dilatation and thinning of the LV wall (Figure 2F through 2M), preserving the H/R ratio that normally declines with DCM ( Figure 2N ). Changes in stroke volume ( Figure 2O 
NR-Enriched Diet Protects the Cardiac NAD + Metabolome in HF
The impact of an NR-enriched diet on the cardiac NAD + metabolome is not known ( Figure 3A ). Mice fed with or without NR were euthanized 3 days after the echocardiography at day 50. Myocardial NAD was decreased in the SRF HKO mice at day 50 as measured by the NAD cycling assay, and the NR diet protected against this drop ( Figure 3B ). Myocardial NAD + and NADH varied in the same direction in all conditions, leaving the NAD + / NADH ratio unchanged ( Figure III in the online-only Data Supplement). Liquid chromatography-mass spectrometry analysis allowed us to provide the levels of NAD + metabolites on a common scale with NAD +13,33 ( Figure 3C through 3L) . SRF HKO mice hearts did not have higher levels of adenosine diphosphate ribose (ADPR) or NAM ( Figure 3D and 3E) . Levels of NADP + and NMN showed a pattern similar to NAD + ( Figure 3F and 3G). NR increased the cardiac levels of nicotinic acid adenine dinucleotide, a sensitive biomarker of increased NAD + metabolism, 29 and methyl-NAM (MeNAM), as well (Figure 3A , 3H through 3J). MeNAM oxidation by AOX1 generates N1-methyl-4-pyridone-5-carboxamide (Me4PY) and releases hydrogen peroxide ( Figure 3A) . Changes in unrelated metabolites were not significant ( Figure 3K and 3L). As shown in the nematode, 34 NR increased the expression of the Nfel2 gene encoding NRF2, whereas its target genes Mt2 and Nox4 were already activated, and G6pdx, as well, in the heart of SRF HKO mice ( Figure 3M  through 3P ). NR treatment in the SRF HK0 hearts limited the level of Myh7 induction, a signature of cardiac stress and metabolic remodeling in the failing heart ( Figure 3Q) .
The liver is a central organ for the regulation of nutrient metabolism. We assessed the NAD + metabolome response in the liver of control and SRF HKO mice (Table IV in the online-only Data Supplement). NR increased the MeNAM and Me4PY levels similarly in both genotypes. It is interesting to note that the liver response to NR diet was more robust in the SRF HKO mice with regard to the increase in the steady-state level of NAD, nicotinic acid adenine dinucleotide, ADPR, and NAM. Because the liver is not targeted by the Srf deletion, it suggests that the HF condition indirectly modifies the balance of NAD synthesis and signaling in the liver.
NR-Enriched Diet Does Not Result in Global Cardiac Protein Deacetylation
The cardiac levels of NAM and ADPR in this HF model are low and show few changes with NR ( Figure 3D and 3E), suggesting that the NR-driven boost in NAD + synthesis is not necessarily translated into a higher level of NAD + consumption by sirtuins and poly(ADP-ribose) polymerases. We performed antiacetyl-K and anti-poly-ADP-ribose Western blot analyses on cardiac proteins from control and SRF HKO mice fed with the chow diet or NR-enriched diets. Just as levels of ADPR were not modulated by SRF HKO 
NR Improves Metabolism of Citrate in HF
Several regulators involved in mitochondrial biogenesis and oxidative metabolism, and lipid metabolism, as well, were repressed in SRF HKO hearts ( Figure VIIA and VIIB in the online-only Data Supplement). Simultaneously, the expression of the glucose transporter Glut1 was increased and expression of Pdk2 was decreased, which can be seen as a trend of the failing heart to increase glycolysis (Figure VIIC in the online-only Data Supplement). NR did not alter the expression of these genes.
There was a trend toward a reduced mitochondrial to genomic DNA ratio in the SRF HKO LV ( Figure 3T ). The NADH-dependent complex I activity and Cox activity was not changed by the NR diet ( Figure 3U and 3V) . Neither the complex I and II maximal respiration rates, nor the apparent K m for ADP, mitochondrial CK coupling, and ADP acceptor control ratio showed any alteration at this stage (day 50) in the SRF HKO LV fibers. These parameters were not altered by NR administration ( Figure VIID through VIIG in the online-only Data Supplement).
We noted that NR treatment resulted in a net increase in acetylation of FOXO1 and p53 ( Figure 3R and Figure V in the online-only Data Supplement). Availability of cytosolic Ac-CoA depends on mitochondrial citrate synthase (CS) production of citrate and conversion to Ac-CoA via the cytosolic enzyme, ATP-citrate lyase (ACL). CS activity was reduced to 65% of control levels in the SRF HKO LV myocardium ( Figure 3W ). It is striking that NR administration protected against the decline of CS activity in the failing heart. This rescue in activity occurred despite a net reduction in protein level in the SRF HKO myocardium that was not rescued by the NR treatment ( Figure VIB in the online-only Data Supplement). It is interesting to that NR also increased cardiac ACL activity in both control and SRF HKO mice ( Figure 3X ). Taken together, these data suggest that NR improves CS and ACL activity, resulting in increased nucleocytoplasmic protein acetylation.
Nmrk2 Gene Is Induced by Inhibition of Alternative NAD + Biosynthetic Pathways in Cultured Cardiomyocytes
To assess the impact of NMRK2 on NAD + biosynthesis relative to the other pathways in cardiomyocytes, we used chemical inhibitors to target the alternative pathways in neonatal rat cardiomyocytes (NRCs) grown in Dulbecco modified Eagle medium containing NAM as the vitamin B3. The glutamine analog azaserin inhibits the glutamine-dependent NAD synthase NADSYN1, 35 which catalyzes the last step of NAD + synthesis from tryptophan and NA ( Figure 1A ). FK866 is a specific inhibitor of Nampt. 36 Azaserin had a slowly repressive effect on NAD pools that resulted in a 50% reduction with respect to nontreated cells at 72 hours ( Figure 4A through 4C) while progressively increasing Nmrk2 expression ( Figure 4D ). FK866 treatment led to a rapid and severe loss of intracellular NAD + but not NADH ( Figure 4A through 4C). Despite this severe loss, NRC could be maintained up to 72 hours in continuous layer with FK866 treatment. FK866 treatment strongly increased Nmrk2 expression at 72 hours ( Figure 4D ). Combined azaserin and FK866 treatment had a similar impact than FK866 alone (Figure 4A through 4D ). Nmrk1 expression did not change in these conditions (not shown).
We tested whether NR could preserve NAD + levels in the presence of FK866. NR slightly increased the baseline level of intracellular NAD + in nontreated NRC, whereas exogenous NAD + had no impact ( Figure 4E ). Both compounds increased the NAD + /NADH ratio (Figure 4F and 4G ). NR fully protected NAD + levels in NRCs treated with FK866, whereas the protection by exogenous NAD + was partial ( Figure 4E ), although both treat- (n=6), +NR (n=5, except for NAM, MeNAM, and Me4PY, n=4, no peak was identified in 1 sample). Data are expressed as means±SEM. M through Q, Expression of genes related to oxidative stress signaling (M through O) and cardiac structural and metabolic remodeling (P and Q). n=5 in each group. R, Representative Western blot analysis of FOXO1 and acetyl-FOXO1 of 3 independent experiments realized in different duplicates for each group. GAPDH is used as a loading control. Right graphs, Quantification of total and acetyl-FOXO1 ratio on GAPDH and acetyl-FOXO1/total FOXO1 ratio in n=5 to 6 animals per group. S, Acetylation level of mitochondrial aconitase 2. Aconitase 2 (75 kDa) was immunoprecipitated using a rabbit polyclonal antibody, and the immunoprecipitate was analyzed by Western blot using a mouse monoclonal anti-Ac(K103) antibody. Inputs were run in a parallel gel and immunoblotted with anti-aconitase 2 and anti-GAPDH for loading control. The ratio of acetylaconitase2/total aconitase2 and aconitase2/GAPDH are shown (right). See accompanying Figure VIA in the online-only Data Supplement for control immunoprecipitation with preimmune rabbit IgG. T through X, LV cardiac tissue was isolated at 50 days after tamoxifen injection in control and SRF HKO mice fed control diet (CD) or NR-enriched diet. DNA and proteins were extracted from parallel samples to quantify mitochondrial to genomic DNA ratio (T) and enzymatic activities: complex I (U), cytochrome oxidase (V), citrate synthase (W), and ATP citrate lyase (X). See associated Figure VII in the online-only Data Supplement. In M through S, data are expressed as mean fold change (FC)±SEM over control group CD. Statistical analysis: Two-way factorial ANOVA for independent samples was used for all panels. ¶P≤0.05, ¶ ¶P≤0.01, ¶ ¶ ¶P≤0.001 for the genotype effect; §P≤0.05, § §P≤0.01, § § §P≤0.001 for the NR treatment effect; ii P≤0.01 for the interaction effect. Post hoc Tukey test: asterisks indicate statistically significant difference versus the control CD group: **P≤0.01. ACL indicates ATP-citrate lyase; ADP, adenosine diphosphate ribose; Cont, control; CS, citrate synthase; IMP, inosine monophosphate; LCMS, liquid chromatographymass spectrometry; NAAD, nicotinic acid adenine dinucleotide; NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMPT, nicotinamide phosphoribosyltransferase; NMN, nicotinamide mononucleotide; and NR, nicotinamide riboside. Mitochondrial stress test in Seahorse analyzer. NRC grown on Seahorse 96-well plates were analyzed for oxygen consumption rate (OCR) at day 8 after 5 days of treatment. K, Basal mitochondrial respiration is calculated from total cellular respiration minus nonmitochondrial respiration. L, ATP production is calculated from basal mitochondrial respiration minus respiration after oligomycin injection. M, Maximal respiration is measured after FCCP injection. See accompanying Figure IX in the onlineonly Data Supplement for other respiration parameters. N through P, Glycolysis stress test in Seahorse analyzer. NRC grown on Seahorse 96-well plates were analyzed at day 8 after 5 days of treatment. N, Glycolysis was measured as a function of extracellular acidification rate (ECAR) after injection of 10 mmol/L glucose. O, Glycolytic capacity as the maximum ECAR following injection of oligomycin. P, Glycolytic reserve as the difference between glycolysis and maximal glycolytic capacity. Throughout the figure, data are expressed as mean fold change (FC)±SEM over the control group, except when indicated. Statistical analysis: a 2-way factorial ANOVA for independent samples was used for A through J. ¶ and § symbols as indicated in the panels; i P≤0.05, ii P≤0.01, iii P≤0.001 for the interaction effect. One-way ANOVA was used for K through P. ¶ P<0. 05 Figure 4E ). At least 100 µmol/L NR was required to rescue the NAD + loss induced by 10 µmol/L FK866 ( Figure 4I ). To assess the functionality of NMRK2 in the absence of a stress like the FK866, we infected NRC with a recombinant adenovirus expressing HA-tagged Nmrk2 cDNA ( Figure 4J ). Overexpression of NMRK2 did not modulate the NAD + levels in NRC. In presence of NR, Nmrk2 overexpression robustly increased the NAD + level by a factor of 6. NR alone slightly increased the NAD + level in control NRC infected with Ad-GFP ( Figure 4J ). In isolated primary cultures of adult rat cardiomyocytes, NR increased intracellular NAD nearly 3-fold, showing that the NMRK pathway is more active in adult rat cardiomyocytes than in NRCs ( Figure VIIIA in the online-only Data Supplement). FK866 reduced NAD levels by a factor of 2 (Figure VIIIA in the online-only Data Supplement) in adult rat cardiomyocytes and increased Nmrk2 expression by a factor of 4.5, whereas azaserin had no impact ( Figure  VIIIB in the online-only Data Supplement). We assessed the impact of NR on oxygen consumption rates in NRC following a mitochondrial stress protocol. NR had no impact on any mitochondrial respiration parameter in NRC at baseline ( Figure 4K through 4M, Figure IX in the online-only Data Supplement). NR increased glycolysis at baseline in a dose-dependent manner ( Figure 4N ), but not the maximal glycolytic capacity ( Figure 4O and 4P). We assessed the capacity of NR to rescue any impact of FK866 on metabolism. FK866 reduced basal oxygen consumption rates and maximal respiration and trended to reduce ATP production (adjusted P value=0.0547) ( Figure 4K through 4M) . Addition of NR at doses that we showed to fully rescue the drop in NAD + levels triggered by the FK866 did not correct these alterations and even further reduced maximal respiration at high doses ( Figure 4K through 4M, Figure  IX in the online-only Data Supplement). FK866 strongly reduced basal glycolysis and glycolytic capacities in NRC. NR strikingly preserved NRC glycolytic capacities to 100% control levels and more in FK866-treated cells and stimulated glycolysis at baseline in nontreated cells in a dose-dependent manner ( Figure 4N through 4P) .
SRF Deficiency-Induced Depression of the Nmrk2 Promoter Is Counterbalanced by the Sensitivity of Nmrk2 Gene to NAD + Depletion and Energetic Stress
Because Nmrk2 expression is activated in vivo on Srf gene inactivation, we addressed the role of the SRF transcription factor in Nmrk2 gene regulation. We identified an SRF binding site with 9/10 bp match to the consensus CC(A/T) 6 GG (CArG) sequence in a conserved 600-bp region between the murine and human genes ( Figure 5A ). We cloned the upstream region and 5ʹ-UTR of the murine Nmrk2 gene (-581/+61) into a luciferase reporter vector and mutated the CArG-like sequence to a motif matching the consensus sequence (5ʹ-CC) or a motif unable to bind SRF (5ʹ-GG) ( Figure 5A ). FK866 increased the expression of the WT construct 8-fold, whereas a consensus CArG reduced the extent of activation (Figure 5B) . The 5ʹ-GG mutation reduced baseline expression by 75% and abolished the response to FK866. The full intergenic 3009-bp sequence upstream of Nmrk2 had a much higher activity, especially in response to FK866 ( Figure 5C ). siRNA-mediated inhibition of Srf reduced, but did not abolish, the induction of endogenous Nmrk2 by FK866 in NRC, suggesting that FK866-triggered activation of the Nmrk2 promoter is partially independent of SRF ( Figure 5D and 5E). FK866 treatment reduces ATP to 50% of the control level in NRC ( Figure 5F ). SRF is major upstream regulator of Ckm gene involved in highenergy phosphate compounds balance. A siRNA-mediated 5-fold knock-down of Ckm gene expression lowered the cellular ATP levels to 70% control level and triggered a 6.8-fold increase in Nmrk2 expression ( Figure 5G 
Nmrk2 Is Induced by the AMPK-PPARα Axis
In line with the previous results, we hypothesized that pathways related to energy failure might activate Nmrk2. The level of phosphorylated AMP-activated protein kinase α (AMPKα), the energy stress-sensing AMP-activated kinase, and its target Ac-CoA carboxylase (ACC) was increased at an early stage when Nmrk2 induction began in the SRF HKO hearts ( Figure 6A and 6B). 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) treatment stimulated AMPK phosphorylation in NRCs and increased NMRK2 protein level in NRCs ( Figure 6C and 6D) . The energetic stress induced by glucose deprivation for 24 hours or FK866 for 48 hours also increased the NMRK2 protein.
AICAR treatment did not modulate NAD + /NADH but robustly induced Nmrk2 expression ( Figure 6E through 6H). To assess whether the effect of AICAR took place at the level of the Nmrk2 promoter, we transfected Nmrk2- 
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luciferase constructs into NRC and treated the cells with AICAR. The p586-Luc, and moreover, the p3009-Luc reporter, was highly responsive to AICAR treatment (Figure 6I and 6J ). Cotransfection of a plasmid overexpressing a dominant negative isoform of AMPK efficiently blunted induction by AICAR ( Figure 6I and 6J) .
Analysis of the 5ʹ-regulatory sequences of Nmrk2 revealed enrichment in putative peroxisome proliferatoractivated receptor (PPAR) binding sites ( Figure 6K ). The fragments -3009/-2552 and -1028/-228 contain most of the activity. By comparison, the activity of the Nmrk2 promoter was very low in cardiac fibroblasts ( Figure 6L ). A, Representative Western blot analysis of cardiac proteins in control and SRF HKO mice at day 9 using antibodies directed against ACC, phospho-ACC (Ser79), AMPKα, and phospho-AMPKα (Thr172). Phosphorylated and total proteins were analyzed on 2 separate gels (gel 1 and 2) and GAPDH antibody was used for loading control. B, Quantification (Continued )
To assess the role of PPAR factors in Nmrk2 gene regulation, we cotransfected NRC with the p3009-Luc reporter and PPAR expression vectors. Only PPARα increased the activity of the Nmrk2 promoter in the presence of its agonist GW7647 ( Figure 6M ). The PPARα antagonist G6471 repressed the Nmrk2 promoter ( Figure 6M ) and blunted the activating effect of AICAR ( Figure 6N ). Neither the PPARβ nor the PPARγ antagonists had any effect on Nmrk2 promoter induction by AICAR. These results establish that Nmrk2 is an AMPK-PPARα-responsive gene that is induced by energy stress in cardiac cells.
NR Preserves Cardiac Function in the TAC Model
To determine whether NR treatment could be useful in other forms of HF, we assessed its efficiency in the TAC model of pressure overload cardiac hypertrophy. NR was administrated starting 2 days after the TAC or SHAM surgery. Kaplan-Meier survival curve analysis showed no significant difference, mainly because of a similar early mortality between the 2 groups within 1 week after TAC ( Figure 7A ). NR treatment reduced the final drop in LV ejection fraction that occurred between the fourth and sixth week after TAC ( Figure 7B and Table V in the online-only Data Supplement). NR did not attenuate the dilatation of the LV chamber and had only a transient effect on the thinning of the interventricular septum ( Figure 7C and 7D) . At euthanization, the cardiac hypertrophy index was similar between the chow diet and NR groups ( Figure 7E) .
The TAC-induced HF resulted in a decrease of the myocardial NAD + pool, which was partially preserved by NR, with little impact on the NAD + /NADH ratio (Figure 7F through 7H ). TAC increased Nmrk2 expression level in the nontreated group and NR-treated group, whereas Nmrk1 expression remained unchanged and Nampt was repressed ( Figure 7I through 7K) . TAC repressed Sirt3 expression, Sirt1 and Ckm expression while increasing the expression of Myh7, Anf, and Bnp ( Figure 7L through 7Q) but NR treatment had no impact on gene expression.
DISCUSSION
We report that depressed NAD + homeostasis and activation of NMRK2 kinase are early and persistent events in a mouse model of DCM leading to heart failure and that administration of NR, the substrate of NMRK2 and most energetically favorable NAD + precursor, prevents deterioration of cardiac function and adverse remodeling ( Figure 8 ).
Altered NAD + homeostasis has been reported in several models of HF including pressure overload, myocardial infarction, and angiotensin 2 infusion. 3, 37, 38 In this context, much attention has focused on the NAMPT enzyme that is repressed in several models of cardiac injuries. 38 On the other hand, we found a robust upregulation of Nmrk2 expression in the heart of SRF HKO developing DCM and a more modest but significant increase following TAC-induced HF. It is interesting that we observed a similar shift from repressed NAMPT to increased NMRK2 in human failing heart. Interrogation of the Gene Expression Omnibus (GEO) database reveals that Nmrk2 is induced in several models of cardiomyopathy related to mutations in the lamin-A (GEO data set GDS2746), 39 Idh2 (GDS4893), 40 PGC1α (GDS4776), 41 or Tfr1 (GSE68745) 42 genes. Considering the relative heterogeneity of molecular functions encoded by these genes, we propose that the activation of the NMRK2 pathway represents a common adaptive mechanism in the failing heart. Here, we show that the Nmrk2 gene can be activated in response to NAMPT inhibition and activation of the energy stress sensor AMPK. In NRCs, we show that this activation depends on PPARα. PPARα is often expressed at lower levels in the adult failing heart, 43 whereas AMPK was shown to activate PPARα in various contexts. 44 Hence, AMPK activation could compensate in part for the lower levels of PPARα to activate Nmrk2. The precise contribution of these actors in the adult failing heart remains an open question. In the case of SRF HKO hearts, it is interesting to note that, despite the fact that SRF is an upstream regulator of Nrmk2 gene that we would expect to be repressed following Srf gene inactivation, SRF is also a major upstream regulator of Ckm gene, which is important to maintain PCr/ADP/ ATP balance, 15, 18 and AMPK is activated early on in the SRF HKO heart (this study). We show in vitro that Ckm depression alone is sufficient to induce Nmrk2 expression. In addition Srf inactivation alters the expression of numerous sarcomeric genes and triggers a severe eccentric remodeling 15 that is likely to further increase the energetic cost of contraction in vivo. A similar phenomenon could HKO male mice were subjected to TAC or SHAM surgery and fed with control chow diet (CD) or NR-enriched diet from day 2 after surgery to day 42. A, Kaplan-Meier survival curve analysis. Log-rank statistic: P>0.05. Color code shown on the right for each group is valid for A through E. B through D, Echocardiography follow-up analysis from baseline (2 days before surgery) to 6 weeks after. E, Heart weight to body weight ratio after euthanization at 6 weeks. F through H, Cardiac NAD + and NADH levels and redox state assessed by the NAD + cycling assay. I through Q, Cardiac mRNA levels of the indicated genes assessed by RT-qPCR. Data are expressed as mean±SEM. Statistical analysis: 2-way ANOVA for independent factors statistical analysis is shown at (Continued ) 
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occur for instance in the lamin-A mutants, which display severe alterations in cardiomyocyte cytoskeletal integrity and in which SRF activity is repressed and Nmrk2 expression induced. 22, 39 In addition to its well-known roles in stimulating fuel oxidation to restore ATP levels, we show that AMPK stimulation induces Nmrk2 expression. NMN synthesis from NR by NMRK enzymes requires a single ATP, whereas synthesis from NAM by NAMPT requires >3 ATP equivalents: one for the autophosphorylation of the enzyme, and 2 (plus a carbohydrate) in formation of phosphoribosyl pyrophosphate (Figure 8 ). Both pathways consume an additional ATP for fusion with NMN to generate the dinucleotide. Hence, the shift from NAMPT to NMRK2 for NAD + synthesis is an energy-sparing mechanism that may be favored in HF. In turn, we show that one of the beneficial actions of NR, at least in vitro, may be to increase glycolysis in cardiomyocytes. These different mechanisms of action may contribute to increase cardiac efficiency, which should be assessed in future studies to establish whether metabolic substrate preference and potentially glucose oxidation, which is associated with a better respiratory quotient and ATP availability, are improved on NR treatment.
Although the NMRK2 pathway is activated in the failing heart of SRF HKO mice, the myocardial NAD + level is depressed, which suggests that circulating and tissue levels of NAD + precursors are insufficient to sustain cardiac NAD + synthesis in mice on a regular rodent diet, stimulating an interest in NR supplementation to correct this defect. A few studies have shown that short-term NAD + supplementation following chronic angiotensin-2 administration 37 or NMN supplementation following ischemia-reperfusion injury 45 or TAC surgery 46 can normalize alterations in NAD + /NADH ratio in the mouse failing heart. It is interesting to note that cells do not take up NMN intact, and, instead, NMN is extracellularly dephosphorylated to NR, such that its cellular conversion to NAD + depends on the NR kinase pathway. 47, 48 We discovered a strongly beneficial effect of NR in the SRF HKO model of HF in the preservation of cardiac function and limitation of cardiac remodeling that was associated with the maintenance of NAD + levels in the heart. NAD + metabolomics and expression analysis showed no evidence for increased levels of PAR, ADPR, Nam, or PARylated proteins, which would indicate a storm of NAD + -consuming activities in this model of Figure 8 . Activation of the NMRK2 pathway to NAD + synthesis as an adaptive energy-sparing mechanism in the failing heart. DCM is a form of pathological cardiac remodeling that is associated with severe energy depletion leading to HF. The energy stress sensor AMP-kinase is an adaptive signaling pathway aiming to preserve energy in the cells. The NAMPT enzyme is a major, rate-limiting step for NAD + synthesis whose energetic cost equals 4 ATP molecules, including 1 converted to AMP, for the synthesis of 1 NAD + . NAMPT is repressed in most forms of HF through an unknown regulatory mechanism. Opposite to this repression, Nmrk2 gene is an AMPK-responsive gene that is activated in several models of DCM and other forms of pathological remodeling such as the pressure-overload cardiac hypertrophy. NMR-kinase 2 allows the synthesis of NAD + at a lower cost of 2 ATP per molecule. Although NR content may be limited in rodent and human diet, NR can easily be provided as a nutraceutical to help the failing heart to maintain NAD + levels. AMPK indicates AMP-activated protein kinase; DCM, dilated cardiomyopathy; HF, heart failure; NAD, nicotinamide adenine dinucleotide; NAM, nicotinamide; NAMPT, nicotinamide phosphoribosyltransferase; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; PPAR, peroxisome proliferator-activated receptor; and PRPP, phosphoribosyl pyrophosphate.
HF. Instead, a progressive loss of Nampt expression, coupled with the known depression of ATP and highenergy phosphates, is postulated to make it challenging for damaged hearts to maintain NAD + homeostasis. Beyond the repletion in myocardial NAD + levels, the most striking NR-reversible deficit we found in HF was depression of CS and ACL activity. Many regulatory processes from gene expression to enzyme activity are controlled by reversible protein Lys acetylation. Although there is a variety of acetylases and deacetylases that are NAD + -dependent and NAD + -independent, production of citrate in mitochondria and its conversion to cytosolic Ac-CoA by the ACL is required to drive changes in substrate fuel selection 2 and protein acetylation level. 8, 49 NR had no impact on the acetylation level of a mitochondrial protein like Aco2 but robustly increased the acetylation level of FOXO1 or p53 transcription factors in SRF HKO hearts and control hearts, suggesting a tight link between NR-derived NAD + synthesis and Ac-CoA availability for posttranslational acetylation of nucleocytosolic proteins. This apparently overrides the ability of SIRT1 to deacetylate these factors. At the present stage, it is difficult to assess the consequences of these modifications. Moreover, there is presently no reason to think that FOXO1 and p53 are the only targets whose acetylation level is modified by long-term NR treatment. Rather, our data suggest that the acetylation levels of FOXO1 and p53 can be considered as surrogate markers of an increase in nucleocytosolic Ac-CoA metabolism.
Last, we observed that NR led to heightened production of Me4PY, a terminal NAM metabolite associated with local production of H 2 O 2 . This pathway was shown to promote life extension in the Caenorhabditis elegans through a hormetic response to a moderate rise in reactive oxygen species, which activates the cytoprotective NRF-2 transcription factor involved in oxidative stress response. 34 In the SRF HKO heart, NR was shown to result in Me4PY simultaneous with induction of NRF-2.
Here, we also show a modest although significant protective effect of NR treatment on the drop of LV ejection fraction observed in the TAC model. The effect of NR in the TAC model seems to be less important than in the DCM model, which may be linked to the different nature of the cardiac stress in these models, ie, pressure overload in the TAC model that increases afterload versus volume overload in DCM that increases preload, and the fact that the Nmrk2 gene is less strongly induced in the TAC model than in the SRF HKO model. We note also that the early mortality induced by the TAC led to an early dropout in the untreated and NR-treated TAC groups that may have introduced a bias by removing from the analysis the animals with the worst outcome.
In conclusion, our work shows that oral NR supplementation is a powerful approach to preserve cardiac function and limit remodeling in DCM, a devastating disease currently lacking effective therapies. Recently, mutations in the de novo NAD + biosynthetic pathway were shown to lead to a new category of genetic diseases called congenital NAD deficiency disorders, which are associated with cardiac and skeletal defects but correctible by niacin supplementation in mouse models of the disease. 50 Our study and previous findings by others 13, [26] [27] [28] suggest that NR has the potential not only to improve the cardiac symptoms in congenital syndromes and acquired HF, but also to act at a systemic level notably on liver metabolism, insulin resistance, and skeletal muscle performances that are altered concomitantly with cardiac defects. However, a limitation of our study is the fact that we did not study the impact of NR on the survival rate of SRF HKO mice and the occurrence of terminal congestive HF. Further work will be required to determine the pharmacokinetics and pharmacodynamics of therapeutic NR administration in animal models and people with HF to enable safe and effective human translation. 
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